Placental growth factor, pregnancy-associated plasma protein-A, soluble receptor for advanced glycation end products, extracellular newly identified receptor for receptor for advanced glycation end products binding protein and high mobility group box 1 levels in patients with acute kidney injury: A cross sectional study

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Zakiyanov, Oskar ^a   Kriha, Vitezslav ^b   Vachek, Jan ^a,c   Zima, Tomas ^a   Tesar, Vladimir ^a   Kalousova, Marta ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Acute kidney injury; Biomarkers; Chronic kidney disease; Extracellular newly identified receptor for advanced glycation end products binding protein; Haemodialysis; Placental growth factor; Pregnancy associated plasma protein A; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; EN RAGE PROTEIN; FERRITIN; HEMOGLOBIN; HIGH MOBILITY GROUP B1 PROTEIN; OROSOMUCOID; PLACENTAL GROWTH FACTOR; PREALBUMIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TRANSFERRIN; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; PAPPA1 PROTEIN, HUMAN; PLACENTA PROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEINURIA; ACUTE KIDNEY INJURY; BLOOD; CZECH REPUBLIC; MIDDLE AGED; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ACUTE KIDNEY INJURY; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; FEMALE; HMGB1 PROTEIN; HUMANS; MIDDLE AGED; PREGNANCY PROTEINS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PREVALENCE; RECEPTORS, IMMUNOLOGIC; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84886731087     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-245     Document Type: Article

References (64)

1. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucenski M, Godinez-Luna T, Svenson LW, Rosenal T, Crit Care 2005 9 6 700 R709 10.1186/cc3879 16280066
2. Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG, Group UoTAKIR, JAMA 2009 302 11 1179 1185 10.1001/jama.2009.1322 19755696
3. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease. Malyszko J, Bachorzewska-Gajewska H, Sitniewska E, Malyszko JS, Poniatowski B, Dobrzycki S, Ren Fail 2008 30 6 625 628 10.1080/08860220802134607 18661413
4. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. Autiero M, Luttun A, Tjwa M, Carmeliet P, J Thromb Haemost 2003 1 7 1356 1370 10.1046/j.1538-7836.2003.00263.x 12871269
5. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B, et al. Nat Med 2002 8 8 831 840 12091877
6. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Imagawa K, Nishida T, Morikawa Y, Takemoto Y, Asai O, et al. Circulation 2009 120 24 2470 2477 10.1161/CIRCULATIONAHA.109.867929 19948974
7. Placental growth factor in patients with decreased renal function. Zakiyanov O, Kalousová M, Zima T, Tesař V, Ren Fail 2011 33 3 291 297 10.3109/0886022X.2011.560402 21401353
8. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA, Proc Natl Acad Sci U S A 1999 96 6 3149 3153 10.1073/pnas.96.6.3149 10077652 (Pubitemid 29148859)
9. Characterization of four human pregnancy-associated plasma proteins. Lin TM, Galbert SP, Kiefer D, Spellacy WN, Gall S, Am J Obstet Gynecol 1974 118 2 223 236 4129188
10. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, Virmani R, Oxvig C, Schwartz RS, N Engl J Med 2001 345 14 1022 1029 10.1056/NEJMoa003147 11586954
11. Pregnancy-associated plasma protein A as an independent mortality predictor in long-term hemodialysis patients. Kalousová M, Benáková H, Kuběna AA, Dusilová-Sulková S, Tesař V, Zima T, Kidney Blood Press Res 2012 35 3 192 201 10.1159/000332086 22123284
12. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Basta G, Atherosclerosis 2008 196 1 9 21 10.1016/j.atherosclerosis.2007.07.025 17826783
13. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Schmidt AM, Yan SD, Yan SF, Stern DM, J Clin Invest 2001 108 7 949 955 11581294 (Pubitemid 32946067)
14. Advanced glycation end products in renal failure. Thornalley PJ, J Ren Nutr 2006 16 3 178 184 10.1053/j.jrn.2006.04.012 16825015 (Pubitemid 43975005)
15. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Jandeleit-Dahm KA, Lassila M, Allen TJ, Ann N Y Acad Sci 2005 1043 759 766 10.1196/annals.1333.088 16037303 (Pubitemid 41123970)
16. Soluble receptor for advanced glycation end products in patients with decreased renal function. Kalousová M, Hodková M, Kazderová M, Fialová J, Tesar V, Dusilová-Sulková S, Zima T, Am J Kidney Dis 2006 47 3 406 411 10.1053/j.ajkd.2005.12.028 16490618 (Pubitemid 43255173)
17. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, Tripepi R, Tripepi G, De Caterina R, Zoccali C, Kidney Int 2010 77 3 225 231 10.1038/ki.2009.419 19924100
18. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, et al. Acta Crystallogr D Biol Crystallogr 2002 58 Pt 3 407 413 11856825 (Pubitemid 34248850)
19. Serum S100A12 (EN-RAGE) levels in patients with decreased renal function and subclinical chronic inflammatory disease. Zakiyanov O, Kalousová M, Kříha V, Zima T, Tesař V, Kidney Blood Press Res 2011 34 6 457 464 10.1159/000329291 21822023
20. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Nakashima A, Carrero JJ, Qureshi AR, Miyamoto T, Anderstam B, Bárány P, Heimbürger O, Stenvinkel P, Lindholm B, Clin J Am Soc Nephrol 2010 5 12 2213 2219 10.2215/CJN.03360410 20847094
21. HMGB1 as a DNA-binding cytokine. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ, J Leukoc Biol 2002 72 6 1084 1091 12488489 (Pubitemid 36008878)
22. HMGB1: endogenous danger signaling. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A, Mol Med 2008 14 7-8 476 484 18431461
23. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H, Shock 2006 26 2 174 179 10.1097/01.shk.0000225404.51320.82 16878026 (Pubitemid 44162504)
24. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Ivanov S, Dragoi AM, Wang X, Dallacosta C, Louten J, Musco G, Sitia G, Yap GS, Wan Y, Biron CA, et al. Blood 2007 110 6 1970 1981 10.1182/blood-2006- 09-044776 17548579 (Pubitemid 47443911)
25. HMG-1 as a late mediator of endotoxin lethality in mice. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. Science 1999 285 5425 248 251 10.1126/science.285.5425.248 10398600 (Pubitemid 29329996)
26. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, et al. Arthritis Rheum 2003 48 4 971 981 10.1002/art.10859 12687539 (Pubitemid 36418239)
27. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M, Maruyama I, Cardiovasc Pathol 2007 16 3 136 143 10.1016/j.carpath.2006.11.006 17502242 (Pubitemid 46729668)
28. HMGB1 contributes to kidney ischemia reperfusion injury. Wu H, Ma J, Wang P, Corpuz TM, Panchapakesan U, Wyburn KR, Chadban SJ, J Am Soc Nephrol 2010 21 11 1878 1890 10.1681/ASN.2009101048 20847143
29. High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ, Mol Med 2008 14 3-4 109 115 18317568 (Pubitemid 351481841)
30. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, workgroup ADQI, Crit Care 2004 8 4 204 R212 10.1186/cc2872 15312219
31. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Ann Intern Med 1999 130 6 461 470 10.7326/0003-4819-130-6-199903160-00002 10075613 (Pubitemid 29135798)
32. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM, Circulation 2003 107 1 87 92 10.1161/01.CIR.0000042700.48769.59 12515748 (Pubitemid 36070938)
33. The ratio of CRP to prealbumin levels predict mortality in patients with hospital-acquired acute kidney injury. Xie Q, Zhou Y, Xu Z, Yang Y, Kuang D, You H, Ma S, Hao C, Gu Y, Lin S, et al. BMC Nephrol 2011 12 30 10.1186/1471-2369- 12-30 21714897
34. Impact of prealbumin levels on mortality in patients with acute kidney injury: an observational cohort study. Perez Valdivieso JR, Bes-Rastrollo M, Monedero P, de Irala J, Lavilla FJ, J Ren Nutr 2008 18 3 262 268 10.1053/j.jrn.2007.11.003 18410882 (Pubitemid 351503903)
35. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, et al. J Intern Med 2003 254 2 132 139 10.1046/j.1365-2796.2003.01180.x 12859694 (Pubitemid 36900436)
36. Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4. Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J, Kidney Int Suppl 2008 111 67 S70 19034331
37. Hemostasis, platelet function and serotonin in acute and chronic renal failure. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, Mysliwiec M, Thromb Res 1996 83 5 351 361 10.1016/0049-3848(96)00145-4 8873344 (Pubitemid 26284109)
38. Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kalousová M, Zima T, Tesar V, Sulková S, Fialová L, Kidney Int Suppl 2003 84 62 S64 12694311
39. Pregnancy-associated plasma protein a and soluble receptor for advanced glycation end products after kidney transplantation. Kalousová M, Bartosová K, Zima T, Skibová J, Teplan V, Viklický O, Kidney Blood Press Res 2007 30 1 31 37 10.1159/000098811 17237617
40. Relationship of pregnancy-associated plasma protein-a to renal function and dialysis modalities. Fialová L, Kalousová M, Soukupová J, Sulková S, Merta M, Jelínková E, Horejsí M, Srámek P, Malbohan I, Mikulíková L, et al. Kidney Blood Press Res 2004 27 2 88 95 10.1159/000076390 14739577 (Pubitemid 38594560)
41. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Sadik NA, Mohamed WA, Ahmed MI, Mol Cell Biochem 2012 359 1-2 73 81 21811803
42. Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T, Nephrol Dial Transplant 2007 22 7 2020 2026 10.1093/ndt/gfm050 17347281 (Pubitemid 47244776)
43. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH, Atherosclerosis 2012 220 1 208 214 10.1016/j.atherosclerosis.2011.07.115 21906738
44. Plasma S100A12 level is associated with cardiovascular disease in hemodialysis patients. Shiotsu Y, Mori Y, Nishimura M, Sakoda C, Tokoro T, Hatta T, Maki N, Iida K, Iwamoto N, Ono T, et al. Clin J Am Soc Nephrol 2011 6 4 718 723 10.2215/CJN.08310910 21258041
45. EN-RAGE (extracellular newly identified receptor for advanced glycation end-products binding protein) and mortality of long-term hemodialysis patients: A prospective observational cohort study. Kalousová M, Kuběna AA, Benáková H, Dusilová-Sulková S, Tesař V, Zima T, Clin Biochem 2012 45 7-8 556 560 22394461
46. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Hochepied T, Berger FG, Baumann H, Libert C, Cytokine Growth Factor Rev 2003 14 1 25 34 10.1016/S1359-6101(02)00054-0 12485617 (Pubitemid 36098429)
47. Role of orosomucoid in the regulation of plasma proteolytic systems during experimental renal failure. Osikov MV, Bull Exp Biol Med 2009 148 1 20 22 10.1007/s10517-009-0629-5 19902086
48. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al. Proc Natl Acad Sci USA 2004 101 1 296 301 10.1073/pnas.2434651100 14695889 (Pubitemid 38084244)
49. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Metz C, Miller EJ, Tracey KJ, et al. Nat Med 2004 10 11 1216 1221 10.1038/nm1124 15502843 (Pubitemid 39540438)
50. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME, EMBO J 2003 22 20 5551 5560 10.1093/emboj/cdg516 14532127 (Pubitemid 37279964)
51. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Lotze MT, Tracey KJ, Nat Rev Immunol 2005 5 4 331 342 10.1038/nri1594 15803152 (Pubitemid 40516158)
52. Therapeutic potential of HMGB1-targeting agents in sepsis. Wang H, Zhu S, Zhou R, Li W, Sama AE, Expert Rev Mol Med 2008 10 32 18980707
53. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Scaffidi P, Misteli T, Bianchi ME, Nature 2002 418 6894 191 195 10.1038/nature00858 12110890 (Pubitemid 34773774)
54. Acute renal failure in critically ill patients: a multinational, multicenter study. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, et al. JAMA 2005 294 7 813 818 10.1001/jama.294.7.813 16106006 (Pubitemid 41175724)
55. Pretransplant pregnancy-associated plasma protein-a as a predictor of chronic allograft nephropathy and posttransplant cardiovascular events. Lauzurica R, Pastor C, Bayés B, Hernández JM, Romero R, Transplantation 2005 80 10 1441 1446 10.1097/01.tp.0000185199.67531.1a 16340789 (Pubitemid 41803627)
56. Elevated pregnancy-associated plasma protein A predicts myocardial dysfunction and death in severe sepsis. Zhang Z, Dai H, Yu Y, Yang J, Chen J, Wu L, Ann Clin Biochem 2013 10.1177/0004563213489275
57. Elevated levels of placental growth factor represent an adaptive host response in sepsis. Yano K, Okada Y, Beldi G, Shih SC, Bodyak N, Okada H, Kang PM, Luscinskas W, Robson SC, Carmeliet P, et al. J Exp Med 2008 205 11 2623 2631 10.1084/jem.20080398 18852292
58. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. Yano K, Liaw PC, Mullington JM, Shih SC, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, et al. J Exp Med 2006 203 6 1447 1458 10.1084/jem.20060375 16702604 (Pubitemid 43877607)
59. Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis. Narvaez-Rivera RM, Rendon A, Salinas-Carmona MC, Rosas-Taraco AG, BMC Infect Dis 2012 12 15 10.1186/1471-2334-12-15 22264245
60. sRAGE is elevated in septic patients and associated with patients outcome. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, Büchler MW, Weigand MA, J Surg Res 2008 147 1 79 83 10.1016/j.jss.2007.07. 014 17981300 (Pubitemid 351626081)
61. S100A12 And soluble receptor for advanced glycation end products levels during human severe sepsis. Achouiti A, Föll D, Vogl T, van Till JW, Laterre PF, Dugernier T, Wittebole X, Boermeester MA, Roth J, van der Poll T, et al. Shock 2013 40 3 188 194 10.1097/SHK.0b013e31829fbc38 23846410
62. Hmgb-1 as a therapeutic target for infectious and inflammatory disorders. Mantell LL, Parrish WR, Ulloa L, Shock 2006 25 1 4 11 10.1097/01.shk. 0000188710.04777.9e 16369179
63. High-mobility group box 1 (HMGB1) protein: friend and foe. Ulloa L, Messmer D, Cytokine Growth Factor Rev 2006 17 3 189 201 10.1016/j.cytogfr.2006. 01.003 16513409 (Pubitemid 43949075)
64. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ, Crit Care Med 2005 33 3 564 573 10.1097/01.CCM.0000155991.88802.4D 15753748 (Pubitemid 40365558)